Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Patidegib Topical Gel 2% in Gorlin Syndrome
2020-000253-27Phase 3Unknown
- Sponsor
- PellePharm
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of patidegib in basal cell carcinoma (BCC) and Basal cell nevus syndrome (BCNS), sponsored by PellePharm. Primary endpoints: Number of facial BCCs removed by surgery and Safety and tolerability of patidegib topical gel 2%. Status: unknown.
02
Drugs
patidegib
03
Conditions
basal cell carcinoma (BCC)Basal cell nevus syndrome (BCNS)
Beyond the preview
Go deeper on 2020-000253-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000253-27.